Neoadjuvant chemoradiotherapy has been a mainstay of the treatment of locally advanced rectal cancer. Programmed cell death protein 1 (PD-1) blockade therapy has demonstrated efficacy in combination with radiation. In this issue, Xiao et al. demonstrate promising efficacy with the addition of PD-1 blockade to neoadjuvant therapy for mismatch-repair proficient rectal cancer.
PURPOSEMelanoma as a subsequent malignant neoplasm has been described among childhood cancer survivors; however, the risk factors and long-term survival are not well understood.METHODSWe assessed…
Alexander Drilon and Alex Miles discuss the importance of shared decision making throughout the course of an NSCLC patient’s treatment.
Call for Papers | Cancer Research | American Association for Cancer Research .aacrcontent ul {list-style-image: url(‘/ImageLibrary/CR/icons/cr_bullet.png’);} .banner{ display: block; width: 100% margin: -20px; } .banner-sm{…
Official websites use .gov A.gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock () or…
Yousef Zakharia, MD, discusses the evolving use of checkpoint inhibitors and emerging triplet regimens in clear cell renal cell carcinoma.
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Nature Cancer – Swanton and colleagues present a clonal expression signature, ORACLE, which, in combination with clinicopathological and molecular risk factors, can predict survival of…
Uncover the future of lymphoma care with Marc Hoffman, Professor, Hematologic Malignancies at the University of Kansas Medical Center.
Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.
